• Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines

    Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Marlow, UK – 4th January 2021 – FOR IMMEDIATE RELEASE CHAIN Biotechnology (CHAIN), a UK-based microbiome therapeutics company, focused on the development of oral vaccines, announced today that Heads of […]

  • CHAIN Biotech Resumes Lab Operations

    Following a 2-month closure, CHAIN reopened its laboratories in Nottingham on the 1st June. This comes after a risk assessment and change to working practices to maintain safe working for staff in the labs and office. MediCity has also implemented new measures in the building to support safe working practices which have also contributed to […]

  • CHAIN announces a new partnership agreement with TdeltaS Ltd

    An Oxford based nutritional company, TdeltaS Ltd (TΔS®), has developed and commercialised a proprietary ketone ester, which can be used as a food to improve human physical performance and cognitive function in health and disease.  The Company’s product, ΔG®, is a ketone monoester that is marketed by HVMN Inc. in the USA for use in their sports […]

Superior and effective microbiome therapeutics

About us

CHAIN Biotechnology Ltd is a microbiome therapeutics company developing oral immuno-therapies.

Read more >

Platform

Our Clostridium Assisted Drug Development (CADD™) platform combines precision engineering with a superior host bacterium to effectively deliver therapeutic payloads to the lower gastrointestinal (GI) tract.

Read more >

Current Job Vacancies

  • Senior Scientist (Immunologist)
  • Scientist (Fermentation)
    • Full time
    • Competitive Salaries

Read more >